Provide first-in-class and best-in-class biological drugs

with affordable prices for global patients

Product Introduction

Currently, PUK is indicated for STEMI. STEMI is caused by continuous obstruction of blood supply, which may lead to large-scale necrosis of myocardial cells. The clinical manifestations are mainly chest pains and ST-segment elevation and dynamic evolution of ECG. Acute ST-segment elevation myocardial infarction is a life-threatening and time-sensitive acute disease. The patient must seek medical treatment in time and undergo coronary artery reperfusion therapy including PCI (percutaneous coronary intervention) or thrombolysis as soon as possible. PUK should be used in the thrombolytic treatment of STEMI.

Unlike Alteplase, the most commonly used thrombolytic drug in China, PUK does not form a covalent complex with protease inhibitors in plasma, which means the blood concentration of PUK and protease inhibitors will not decrease. This inhibitor is directly related to the prevention of systemic bleeding, for a higher inhibitor concentration is beneficial for reducing the rate of intracranial hemorrhage in patients.

The new generation of fibrin-specific thrombolytic drug in china

China’s only commercialized recombinant human prourokinase product

Listed in the NRDL in 2017 and 2019

8 Authoritative STEMI guidelines recommended

The highest recanalization rate of 85% and the lowest incidence of intracerebralhemorrhage of 0.29%

Have excellent efficacy and outstanding safety for treating thrombosis indications such as AIS and APE

The first Category I Major Innovative Biologic Drug during the 11th Five-Year Plan

AIS received funding under the National Science and Technology Major Project — Major Innovative Drug Development in the 13th Five-Year Plan

Mechanism of Action

Activation Phase

Formation Phase of PUK + plasminogen + fibrin fragment E

Rapid Thrombolysis